Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
The latest from Dr. Falk Pharma
Welcome to our Newsroom, providing you with the latest news, press releases, clinical trial announcements, events, and more from Dr. Falk Pharma.
Follow us on LinkedIn!
Following the footsteps of our founder
Herbert Falk's granddaughter Elena decided to follow her grandpa's footsteps. Why? Find out more and follow Elena on her journey.
More
Dosing of the First United States Patient
...and expansion of the Phase 2b Study of Naronapride in Gastroparesis
More
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
More
Corum – Place To Share
Read about yesterday's groundbreaking ceremony for the building in which we will be working in as of 2026.
More
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
More
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
More
UEG Week 2023
We look forward to seeing you on booth C1-22 in Copenhagen from October 14 – 17!
More
Eating should be a pleasure
What does it feel like to eat when you know that each bite will hurt when swallowing?
More
EoE Week 2023
We support this year’s EoE Week in order to help raise awareness for eosinophilic esophagitis.
More
Management change at Dr. Falk Pharma GmbH
Kai Pinkernell takes over as Managing Director Science & Innovation.
More
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
More
3000 LinkedIn-Followers!
Thank you very much!
Together we know more. Together we do more.
More
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
More
Launch of Dr. Falk Pharma in Italy
We are pleased to introduce our Italian affiliate!
More
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
More
Launch of Dr. Falk Pharma in France
We are pleased to introduce our French affiliate!
More
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
More
International Liver Congress™ in London
We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!
More
Digestive Disease Week® 2022
We look forward to 2 exciting presentations on day 4 of this year’s DDW!
More
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
More
Response to the Ukraine crisis
Dr. Falk Pharma supports APOTHEKER HELFEN e.V.
More
Future starts here
Plans for the future Falk Campus in Freiburg-Nord finalized.
More
Together we advance PR600
Investigational New Drug Application for PR600 expected in 3Q 2022.
More